Syndax Pharmaceuticals Profit Margin

The latest profit margin for SNDX is -112.01% as of March 2026. That compares with -757.52% in the prior-year period — up 85.2% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Syndax Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, SNDX's profit margin moved from -757.52% to -112.01% — a 85.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Syndax Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, SNDX currently prints -112.01% for profit margin, while the sector average sits near 15.29%. That is roughly 832.4% below the sector mean. Large gaps often invite a closer look at Syndax Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Syndax Pharmaceuticals converts resources into returns. At -112.01%, SNDX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -757.52% in the prior-year period — up 85.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SNDX's profit margin (-112.01%), review year-over-year change from -757.52%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.